<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000799</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 281</org_study_id>
    <secondary_id>GS-93-105</secondary_id>
    <secondary_id>FDA 231A</secondary_id>
    <nct_id>NCT00000799</nct_id>
  </id_info>
  <brief_title>HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol</brief_title>
  <official_title>HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC) for&#xD;
      treatment of small peripheral cytomegalovirus (CMV) retinitis lesions. To provide data on the&#xD;
      relative safety and efficacy of 2 doses of HPMPC as maintenance regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Stage 1, up to 30 patients are randomized to either observation with deferral of treatment&#xD;
      until the retinitis progresses (observation group), or to intravenous HPMPC at the higher&#xD;
      dose for two consecutive weekly induction doses, followed by the lower dose every other week&#xD;
      for maintenance. In Stage 2, up to 70 patients are randomized to observation or to HPMPC at&#xD;
      the higher dose for two consecutive weekly induction doses followed by either dose every&#xD;
      other week for maintenance, for a total of three treatment groups. Concomitant saline&#xD;
      hydration and probenecid are administered to patients receiving HPMPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 1996</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Cytomegalovirus Retinitis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Oral trimethoprim/sulfamethoxazole.&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
          -  Itraconazole.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Filgrastim (G-CSF).&#xD;
&#xD;
          -  Antiretroviral agents.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  AIDS by CDC criteria.&#xD;
&#xD;
          -  CMV retinitis as determined by a SOCA-certified ophthalmologist, with lesion size,&#xD;
             location, and severity as specified in the Disease Status field.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylaxis with anti-CMV agents.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Ongoing therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune&#xD;
             immunoglobulin, or other investigational agents with anti-CMV activity.&#xD;
&#xD;
          -  Therapy with nephrotoxic drugs, including amphotericin B, aminoglycoside antibiotics,&#xD;
             vidarabine, and intravenous pentamidine.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of renal disease or renal dialysis.&#xD;
&#xD;
          -  History of clinically significant cardiac disease, including symptoms of ischemia,&#xD;
             congestive heart failure, or arrhythmia.&#xD;
&#xD;
          -  History of clinically significant probenecid allergy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune&#xD;
             immunoglobulin, or other investigational agents with anti-CMV activity.&#xD;
&#xD;
          -  Therapy with nephrotoxic drugs within the past 7 days, including amphotericin B,&#xD;
             aminoglycoside antibiotics, vidarabine, and intravenous pentamidine.&#xD;
&#xD;
        Drug or alcohol abuse sufficient to hinder compliance with study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD - Shiley Eye Ctr / SOCA</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>920930946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA - Jules Stein Eye Institute / SOCA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900957003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF - San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ / SOCA</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp / SOCA</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212879217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Univ Med Ctr / SOCA</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina / SOCA</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med. 1997 Feb 15;126(4):264-74. doi: 10.7326/0003-4819-126-4-199702150-00002.</citation>
    <PMID>9036798</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <keyword>Retinitis</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>cidofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Retinitis</mesh_term>
    <mesh_term>Retinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cidofovir</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

